254 related articles for article (PubMed ID: 31313716)
1. The evolving role of cytoreductive nephrectomy: incorporating genomics of metastatic renal cell carcinoma into treatment decisions.
Mano R; Gopal N; Hakimi AA
Curr Opin Urol; 2019 Sep; 29(5):531-539. PubMed ID: 31313716
[TBL] [Abstract][Full Text] [Related]
2. Evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma of variant histology.
Alhalabi O; Karam JA; Tannir NM
Curr Opin Urol; 2019 Sep; 29(5):521-525. PubMed ID: 31305271
[TBL] [Abstract][Full Text] [Related]
3. Is cytoreductive nephrectomy relevant in the immunotherapy era?
Singla N; Ghandour RA; Margulis V
Curr Opin Urol; 2019 Sep; 29(5):526-530. PubMed ID: 31305273
[TBL] [Abstract][Full Text] [Related]
4. The evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma.
Graham J; Bhindi B; Heng DYC
Curr Opin Urol; 2019 Sep; 29(5):507-512. PubMed ID: 31305275
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors and risk classifications for patients with metastatic renal cell carcinoma.
Shinohara N; Abe T
Int J Urol; 2015 Oct; 22(10):888-97. PubMed ID: 26147084
[TBL] [Abstract][Full Text] [Related]
6. The impact of targeted therapy on management of metastatic renal cell carcinoma: trends in systemic therapy and cytoreductive nephrectomy utilization.
Psutka SP; Kim SP; Gross CP; Van Houten H; Thompson RH; Abouassaly R; Weight C; Boorjian SA; Leibovich BC; Shah ND
Urology; 2015 Feb; 85(2):442-50. PubMed ID: 25623717
[TBL] [Abstract][Full Text] [Related]
7. The use of cytoreductive nephrectomy in patients with renal cell carcinoma.
Ghandour RA; Singla N; Margulis V
Expert Rev Anticancer Ther; 2019 May; 19(5):405-411. PubMed ID: 31020871
[TBL] [Abstract][Full Text] [Related]
8. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma.
Bhindi B; Abel EJ; Albiges L; Bensalah K; Boorjian SA; Daneshmand S; Karam JA; Mason RJ; Powles T; Bex A
Eur Urol; 2019 Jan; 75(1):111-128. PubMed ID: 30467042
[TBL] [Abstract][Full Text] [Related]
9. Comparative Survival following Initial Cytoreductive Nephrectomy versus Initial Targeted Therapy for Metastatic Renal Cell Carcinoma.
Bhindi B; Habermann EB; Mason RJ; Costello BA; Pagliaro LC; Thompson RH; Leibovich BC; Boorjian SA
J Urol; 2018 Sep; 200(3):528-534. PubMed ID: 29574109
[TBL] [Abstract][Full Text] [Related]
10. The role of cytoreductive surgery in the era of targeted agents.
Noe A; Stewart GD; Bex A
Curr Opin Urol; 2015 Sep; 25(5):374-80. PubMed ID: 26075568
[TBL] [Abstract][Full Text] [Related]
11. Patient selection for cytoreductive nephrectomy in combination with targeted therapies or immune checkpoint inhibitors.
Shapiro DD; Abel EJ
Curr Opin Urol; 2019 Sep; 29(5):513-520. PubMed ID: 31305274
[TBL] [Abstract][Full Text] [Related]
12. Analysis of pre-operative variables for identifying patients who might benefit from upfront cytoreductive nephrectomy for metastatic renal cell carcinoma in the targeted therapy era.
You D; Jeong IG; Song C; Lee JL; Hong B; Hong JH; Ahn H; Kim CS
Jpn J Clin Oncol; 2015 Jan; 45(1):96-102. PubMed ID: 25341544
[TBL] [Abstract][Full Text] [Related]
13. Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy.
Kwan KG; Kapoor A
Curr Opin Support Palliat Care; 2009 Sep; 3(3):157-65. PubMed ID: 19528804
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of cytoreductive nephrectomy combined with targeted therapy for metastatic renal cell carcinoma: a meta-analysis.
Hong X; Li F; Tang K; Pang S; Lin G; Li S; Bao J; Tan W
Int Urol Nephrol; 2016 Jun; 48(6):967-75. PubMed ID: 26861063
[TBL] [Abstract][Full Text] [Related]
15. External validation of a predictive model of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma.
Marconi L; de Bruijn R; van Werkhoven E; Beisland C; Fife K; Heidenreich A; Kapoor A; Karam J; Kauffmann C; Klatte T; Ljungberg B; Matin S; Sjoberg D; Staehler M; Stewart GD; Tanguay S; Uzzo R; Welsh S; Wood L; Wood C; Bex A
World J Urol; 2018 Dec; 36(12):1973-1980. PubMed ID: 30069581
[TBL] [Abstract][Full Text] [Related]
16. Role of cytoreductive nephrectomy for Japanese patients with primary renal cell carcinoma in the cytokine and targeted therapy era.
Tatsugami K; Shinohara N; Kondo T; Yamasaki T; Eto M; Tsushima T; Terachi T; Naito S;
Int J Urol; 2015 Aug; 22(8):736-40. PubMed ID: 25988793
[TBL] [Abstract][Full Text] [Related]
17. The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy.
Rini BI; Campbell SC
J Urol; 2007 Jun; 177(6):1978-84. PubMed ID: 17509276
[TBL] [Abstract][Full Text] [Related]
18. Temporal trends and factors associated with systemic therapy after cytoreductive nephrectomy: an analysis of the National Cancer Database.
Smaldone MC; Handorf E; Kim SP; Thompson RH; Costello BA; Corcoran AT; Wong YN; Uzzo RG; Leibovich BC; Kutikov A; Boorjian SA
J Urol; 2015 Apr; 193(4):1108-13. PubMed ID: 25444991
[TBL] [Abstract][Full Text] [Related]
19. Oncological outcomes after cytoreductive nephrectomy for patients with metastatic renal cell carcinoma with inferior vena caval tumor thrombus.
Miyake H; Sugiyama T; Aki R; Matsushita Y; Tamura K; Motoyama D; Ito T; Otsuka A
Int J Clin Oncol; 2018 Jun; 23(3):553-558. PubMed ID: 29332206
[TBL] [Abstract][Full Text] [Related]
20. Cytoreductive nephrectomy with thrombectomy before targeted therapy improves survival for metastatic renal cell carcinoma with venous tumor thrombus: a single-center experience.
Qi N; Wu P; Chen J; Li T; Ning X; Wang J; Gong K
World J Surg Oncol; 2017 Jan; 15(1):4. PubMed ID: 28056988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
